Nanjing Puenrui Biotechnology
Oncology precision medicine R&D and CRO services
About Nanjing Puenrui Biotechnology
Nanjing Puenrui Biotechnology Co., Ltd. is a high-tech enterprise specializing in precision oncology diagnostics. Founded in 2015 by founder and chairman Zhu Yanping, the company is recognized as one of the first institutions in China to conduct in-vivo pharmacodynamic testing for individualized treatment. The firm serves over 100 domestic and international pharmaceutical companies with CRO services and provides individualized precision treatment services for cancer patients. Its business model centers on offering a one-stop service platform for tumor efficacy evaluation using its proprietary technologies and providing R&D for companion diagnostics.
Puenrui's core offering is its Patient-Derived Tumor Xenograft (PDTX) model platform, which includes patented technologies like FastPDTX® and HIS-PDTX (a dual-humanized model). These models simulate clinical trials in mice to assess the effectiveness of anti-tumor drugs, offering a faster and more precise method for drug sensitivity testing. The company has established a substantial biobank and database containing pharmacodynamic phenotype data, clinical phenotype information, and lifeomics data from living tumor tissues. This resource supports the development of companion diagnostic kits for anti-tumor drugs and new drug target discovery.
Financially, Puenrui has secured significant backing from various government and venture capital funds, including the National Science and Technology Achievement Transformation Guidance Fund. The company has completed multiple funding rounds, including a Series A in January 2019 and a Series B in December 2021 that raised over 200 million RMB. These funds are allocated to expanding the tumor biobank, enhancing CRO service capabilities, and accelerating the development and manufacturing of IVD test kits in its GMP-compliant facility. The company has received numerous accolades, including the title of "Nanjing Unicorn Cultivation Enterprise" in 2022.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2022 | $28M | $110M | Vision Plus Capital | ↗ |
Growth signals
Latest recorded traffic for Nanjing Puenrui Biotechnology is 120 monthly website visits. Nanjing Puenrui Biotechnology's team grew 0% over the past year.
Open positions
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nanjing Puenrui Biotechnology in the Nanjing City ecosystem
The Nanjing Puenrui Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Vision Plus Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Puenrui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Puenrui Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.